Lineage Cell Therapeutics Files 8-K

TL;DR

LCTX filed a routine 8-K, no new material news.

AI Summary

Lineage Cell Therapeutics, Inc. filed an 8-K on May 14, 2024, to report other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This filing indicates routine corporate reporting by Lineage Cell Therapeutics, Inc. to the SEC, without disclosing new material information.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting purposes and does not contain any new material information that would immediately impact the company's risk profile.

Key Players & Entities

• Lineage Cell Therapeutics, Inc. (company) — Registrant
• May 14, 2024 (date) — Date of Report
• 001-12830 (other) — Commission File Number
• 94-3127919 (other) — IRS Employer Identification No.
• 2173 Salk Avenue, Suite 200, Carlsbad, California 92008 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $39,966,424 — ng an aggregate offering price of up to $39,966,424 (the "ATM Shares") through B. Riley Sec

Filing Documents

• lctx-20240514.htm (8-K) — 41KB
• lctx-ex5_1.htm (EX-5.1) — 26KB
• img133474293_0.jpg (GRAPHIC) — 8KB
• 0000950170-24-059689.txt ( ) — 191KB
• lctx-20240514.xsd (EX-101.SCH) — 23KB
• lctx-20240514_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On May 14, 2024, Lineage Cell Therapeutics, Inc. (the "Company") filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement dated May 14, 2024 (the "Prospectus Supplement") to the prospectus dated May 14, 2024 (the "Prospectus") that forms a part of the Company's shelf registration statement on Form S-3 (File No. 333-277758) filed by the Company with the SEC on March 7, 2024 and declared effective by the SEC on May 14, 2024 (the "Registration Statement"). The Prospectus Supplement relates to the offer and sale of the Company's common shares, from time to time, having an aggregate offering price of up to $39,966,424 (the "ATM Shares") through B. Riley Securities, Inc. ("B. Riley") acting as sales agent, pursuant to that sales agreement dated March 22, 2024 entered into between the Company and B. Riley, as previously reported by the Company in its Current Report on Form 8-K filed with the SEC on March 22, 2024.The ATM Shares are being offered and sold pursuant to the Registration Statement, the Prospectus, and the Prospectus Supplement. This report shall not constitute an offer to sell or the solicitation of an offer to buy the ATM Shares, nor shall there be any sale of the ATM Shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A copy of the opinion of Sheppard Mullin Richter & Hampton, LLP relating to the legality of the ATM Shares covered by the Prospectus Supplement is attached hereto as Exhibit 5.1 and is incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Sheppard Mullin Richter & Hampton, LLP 23.1 Consent of Sheppard Mullin Richter & Hampton, LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lineage Cell Therapeutics, Inc. Date: May 14, 2024 By: /s/ George A. Samuel III Name: Title: George A. Samuel III General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR